Translational Development Acquisition Corp. (TDACU) Change in Accured Expenses (2024 - 2026)

Translational Development Acquisition (TDACU) has 3 years of Change in Accured Expenses data on file, last reported at -$12988.0 in Q1 2026.

• Quarterly Change in Accured Expenses fell 114.09% year-over-year to -$12988.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$76154.0 (changed N/A YoY) and the FY2025 annual result came in at $29008.0, up 106.45% from the prior year.
• Change in Accured Expenses fell to -$12988.0 in Q1 2026, from -$8772.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $92174.0 in Q1 2025 to a low of -$469542.0 in Q4 2024.
• A 3-year average of -$61817.4 and a median of -$8772.0 in 2025 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2025 — Change in Accured Expenses jumped 98.13% — and 2026, when it sank 114.09%.
• Tracing TDACU's Change in Accured Expenses over 3 years: stood at -$469542.0 in 2024, then jumped by 98.13% to -$8772.0 in 2025, then tumbled by 48.06% to -$12988.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$12988.0 (Q1 2026), -$8772.0 (Q4 2025), and $8163.0 (Q3 2025), per Business Quant data.